Floatz logo

Devimistat

Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)

Wake Forest University Health SciencesSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) cohort.

Asset / SponsorPhaseRating
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Cytosin-Arabinosid
Alice Mims
Phase 3BBB
Idarubicine
Bruno C. Medeiros
Phase 2BBB
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BBB
ETOPOSIDE
Alice Mims
Phase 3BBB

View all 50 →

Same molecule, other indications

Devimistat is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
acute myeloid leukemiaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →